Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAMP3 | O60896 | 14/20 | 0.45 |
| ▸ | CALCR | P30988 | 14/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.43 |
| ▸ | GRB2 | P62993 | 1/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.43 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13084645 | 0.94 | RAMP3 (0.47) | RAMP3CALCROPRM1OPRK1GRB2 | |
| SCHEMBL12314876 | 0.94 | RAMP3 (0.47) | RAMP3CALCROPRM1OPRK1GRB2 | |
| SCHEMBL12314880 | 0.94 | RAMP3 (0.47) | RAMP3CALCROPRM1OPRK1GRB2 | |
| SCHEMBL13084700 | 0.94 | RAMP3 (0.47) | RAMP3CALCROPRM1OPRK1GRB2 | |
| SCHEMBL14452355 | 0.90 | GRB2 (0.45) | RAMP3CALCROPRM1OPRK1GRB2 | |
| SCHEMBL16351228 | 0.90 | RAMP3 (0.41) | RAMP3CALCRGRB2 | |
| SCHEMBL16351204 | 0.89 | RAMP3 (0.46) | RAMP3CALCROPRM1OPRK1GRB2 | |
| SCHEMBL12339085 | 0.89 | RAMP3 (0.46) | RAMP3CALCROPRM1OPRK1GRB2 | |
| SCHEMBL16351202 | 0.89 | OPRM1 (0.49) | RAMP3CALCROPRM1OPRK1GRB2 | |
| SCHEMBL13084631 | 0.85 | GRB2 (0.50) | RAMP3CALCROPRM1OPRK1GRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110262366-A1 | COMPOUNDS FOR TARGETING ENDOTHELIAL CELLS, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THEIR USE | BRACCO INTERNATIONAL B.V. (NL) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262366-A1 | COMPOUNDS FOR TARGETING ENDOTHELIAL CELLS, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THEIR USE | VCAM1, FLT1, EDNRA | RAMP3 1333/4885CALCR 928/4885OPRM1 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.